Jan 3, 2018

New drug treating rare form of blindness costs $850,000

A new drug treating a rare form of blindness will cost $850,000. Photo: Courtesy of Spark Therapeutics

Spark Therapeutics is charging $850,000 for its recently approved gene therapy drug, Luxturna, which treats a rare eye condition that leads to blindness. The actual price will be lower after Spark negotiates discounts with health insurers, but uninsured patients and people with high deductibles and coinsurance rates pay based on the list price.

Why it matters: Luxturna is now the most expensive drug on the market, although many other rare-disease drugs also cost more than $500,000.

More details: The drug company said it is working with insurers to offer rebates if Luxturna doesn't work, and it is talking with the federal government to allow insurers to pay for the therapy over several years instead of having to make one large upfront payment.

Go deeper: The $850,000 price tag for Luxturna is above what is considered to be a fair, value-based price, according to a draft analysis from a group that evaluates drug prices.

Go deeper

Snapchat will no longer promote Trump's account in Discover

Photo: Chip Somodevilla/Getty Images

Snapchat will no longer promote President Trump's account on its "Discover" page of curated content, a spokesperson tells Axios, after Trump tweeted comments that some suggested glorified violence amid racial justice protests.

Why it matters: Snapchat is taking action on the president's account for comments he made elsewhere. That's going farther than other big tech firms and signals a commitment to aligning content served to users with core values, rather than making moderation decisions based narrowly on each post made on its own platform.

Updated 43 mins ago - Politics & Policy

Esper catches White House off guard with opposition to military use, photo op

Defense Secretary Mark Esper said at a press briefing Wednesday that he does not support invoking the Insurrection Act, an 1807 law that permits the president to use active-duty troops on U.S. soil, in order to quell protests against racial injustice.

Why it matters: President Trump threatened this week to deploy military forces if state and local governments aren't able to squash violent protests. Axios reported on Wednesday that Trump is backing off the idea for now, but that he hasn't ruled it out.

Chinese coronavirus test maker agreed to build a Xinjiang gene bank

Illustration: Annelise Capossela/Axios

A leading Chinese gene sequencing and biomedical firm that said it would build a gene bank in Xinjiang is supplying coronavirus tests around the world.

Why it matters: U.S. officials are worried that widespread coronavirus testing may provide an opportunity for state-connected companies to compile massive DNA databases for research as well as genetics-based surveillance.